Generic Medicine Info
Indications and Dosage
Adult: 1 mg immediately before bedtime, may increase to 2 or 3 mg if necessary. Max: 3 mg daily.
Elderly: Max: 2 mg daily.
Special Patient Group
Debilitated patients and patients taking potent CYP3A4 inhibitors: Max: 2 mg at bedtime.
Hepatic Impairment
Severe: Max: 2 mg daily.
Should be taken on an empty stomach. Take immediately before going to bed. Avoid taking after a heavy meal.
Special Precautions
Patient w/ history of drug dependence, resp compromise (e.g. COPD, sleep apnoea), depression, diseases or conditions that could affect metabolism or haemodynamic responses. Avoid abrupt withdrawal. Severe hepatic impairment. Elderly and debilitated patients. Pregnancy and lactation.
Adverse Reactions
CNS depressant effects (e.g. impaired alertness and motor coordination), abnormal thinking, behavioural changes (e.g. hallucinations), amnesia and other neuropsychiatric symptoms, exacerbation of depression, suicidal thinking, complex behaviours (e.g. "sleep-driving"), unpleasant taste, headache, somnolence, resp infection, dizziness, dry mouth, dyspepsia, nausea, nervousness, rash, viral infection, anxiety, vomiting, confusion, decreased libido, dysmenorrhoea, gynecomastia, dysosmia.
Potentially Fatal: Anaphylaxis and angioedema.
Patient Counseling Information
May impair ability to drive, operate machinery or other activities that require alertness. Take the medication when there is at least 7-8 hr of sleep.
Monitoring Parameters
Monitor patients w/ history of drug addiction, abuse, tolerance or dependence. Monitor patients for abnormal thinking or behaviour.
Symptoms: Impairment of consciousness ranging from somnolence to coma. Management: Symptomatic and supportive treatment w/ immediate gastric lavage. Administer IV fluids as needed. May give flumazenil.
Drug Interactions
Additive effects w/ CNS depressants (e.g. benzodiazepine, opioids, TCAs). Decreased exposure and effect w/ CYP3A4 inducers (e.g. rifampicin). Increased exposure and effect w/ CYP3A4 inhibitors (e.g. ketoconazole).
Food Interaction
Onset of action may be reduced if taken w/ or immediately after a high-fat/heavy meal. Additive psychomotor impairment w/ alcohol.
Description: Eszopiclone may interact w/ γ-aminobutyric acid (GABA) receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.
Absorption: Rapidly absorbed from the GI tract. Delayed w/ high-fat or heavy meal. Time to peak plasma concentration: Approx 1 hr.
Distribution: Plasma protein binding: 52-59%.
Metabolism: Extensively metabolised via oxidation and demethylation by CYP3A4 and CYP2E1 isoenzymes to several active and inactive metabolites.
Excretion: Via urine (up to 75%; as metabolites). Half-life: Approx 6 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Eszopiclone, CID=969472, (accessed on Jan. 22, 2020)

Store at 25°C.
MIMS Class
Hypnotics & Sedatives
ATC Classification
N05CF04 - eszopiclone ; Belongs to the class of benzodiazepine related drugs. Used as hypnotics and sedatives.
Anon. Eszopiclone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 06/11/2014.

Buckingham R (ed). Eszopiclone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 06/11/2014.

FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose. U.S. FDA. Accessed 25/08/2015.

Lunesta Tablet, Coated (Sunovion). DailyMed. Source: U.S. National Library of Medicine. Accessed 06/11/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Eszopiclone. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 06/11/2014.

Wickersham RM. Eszopiclone. Facts and Comparisons [online]. St. Louis, MO. Wolters Kluwer Clinical Drug Information, Inc. Accessed 06/11/2014.

Disclaimer: This information is independently developed by MIMS based on Eszopiclone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in